Skip to main content
Literatur
Zurück zum Zitat Breitenstein B, Brückl TM, Ising M et al (2015) ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B(4): 274–283 Breitenstein B, Brückl TM, Ising M et al (2015) ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B(4): 274–283
Zurück zum Zitat Breitenstein B, Scheuer S, Brückl TM et al (2016) Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res 73: 86–95 Breitenstein B, Scheuer S, Brückl TM et al (2016) Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res 73: 86–95
Zurück zum Zitat Faber MS, Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76: 178–184 Faber MS, Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76: 178–184
Zurück zum Zitat Gründer G, Baumann P, Conca A et al; für die TDM-Gruppe der AGNP (2014) Therapeutisches Drug-Monitoring in der Psychiatrie. 85: 847855 Gründer G, Baumann P, Conca A et al; für die TDM-Gruppe der AGNP (2014) Therapeutisches Drug-Monitoring in der Psychiatrie. 85: 847855
Zurück zum Zitat Haen E (2014) Arzneimittelinteraktionen. Nervenarzt 85: 417–426 Haen E (2014) Arzneimittelinteraktionen. Nervenarzt 85: 417–426
Zurück zum Zitat Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93: 402–408 Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93: 402–408
Zurück zum Zitat Hicks JK, Bishop JR, Sangkuhl K et al; Clinical Pharmacogenetics Implementation Consortium (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 98: 127–134 Hicks JK, Bishop JR, Sangkuhl K et al; Clinical Pharmacogenetics Implementation Consortium (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 98: 127–134
Zurück zum Zitat Hiemke C, Baumann P, Bergemann N et al (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44: 195–235 Hiemke C, Baumann P, Bergemann N et al (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44: 195–235
Zurück zum Zitat Hiemke C, Eckermann G (2014) Kombinationstherapie/Polypharmazie: Interaktionen von Psychopharmaka. Psychopharmakotherapie 21: 269–279 Hiemke C, Eckermann G (2014) Kombinationstherapie/Polypharmazie: Interaktionen von Psychopharmaka. Psychopharmakotherapie 21: 269–279
Zurück zum Zitat Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 106: 97–132 Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 106: 97–132
Zurück zum Zitat Ostad Haji E, Tadic A, Wagner S et al (2013) Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry 46: 261–266 Ostad Haji E, Tadic A, Wagner S et al (2013) Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry 46: 261–266
Zurück zum Zitat Schatzberg AF, DeBattista, Lazzeroni LC et al (2015) ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry 172: 751–159 Schatzberg AF, DeBattista, Lazzeroni LC et al (2015) ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry 172: 751–159
Zurück zum Zitat Stingl J, Viviani R (2015) Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med 277(2): 167–177 Stingl J, Viviani R (2015) Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med 277(2): 167–177
Zurück zum Zitat Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeutics 138: 103–141 Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeutics 138: 103–141
Metadaten
Titel
Pharmakokinetik und Arzneimittelinteraktionen
verfasst von
Prof. Dr. rer. nat. C. Hiemke
Prof. Dr. med. O. Benkert
Copyright-Jahr
2017
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-50333-1_16